For research use only. Not for therapeutic Use.
NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn’s disease and ulcerative colitis[1][2].
NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels[2].
NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract[2].
| Catalog Number | I040081 |
| CAS Number | 2389235-01-0 |
| Synonyms | 2-[3,5-bis[(6-methylpyridin-2-yl)oxy]phenoxy]-6-methylpyridine |
| Molecular Formula | C24H21N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H21N3O3/c1-16-7-4-10-22(25-16)28-19-13-20(29-23-11-5-8-17(2)26-23)15-21(14-19)30-24-12-6-9-18(3)27-24/h4-15H,1-3H3 |
| InChIKey | OPUQKVNCXCWRLR-UHFFFAOYSA-N |
| SMILES | CC1=NC(=CC=C1)OC2=CC(=CC(=C2)OC3=CC=CC(=N3)C)OC4=CC=CC(=N4)C |
| Reference | [1]. Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203(12):3407-3415. [2]. Leber A, et.al. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1 [published online ahead of print, 2019 Oct 25]. Drug Chem Toxicol. 2019;1-6. |
